Episode 224 - Wyatt McDonnell - CEO of Infinimmune

<p>On this episode of the podcast we feature CEO &amp; Co-Founder of Infinimmune, Wyatt McDonnell, to discuss a hugely impressive &amp; milestone-rich journey since founding in 2022. </p><p>Infinimmune was founded on the belief that human disease is best treated with truly human therapeutics. Their discovery platform, developed by Wyatt and his five former 10X Genomics colleagues, has already been tapped by Merck in a partnering deal potentially worth $800million plus. The first two of their immune system-derived antibodies are heading toward the clinic in Atopic Dermatitis, and the Series A round to fund those trials attracted interest from Regeneron&#39;s venture arm.</p><p>On a more personal note, this episode also offers great insight into Wyatt&#39;s own journey into biotech and the entrepreneurial traits that lead to him going &#39;all-in&#39; on Infinimmune. He also gives his advice for anyone in a similar position looking to go on that journey.</p>